Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A. Plasencia C, et al. Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19. Clin Exp Rheumatol. 2016. PMID: 27214767
Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.
Plasencia C, Kneepkens EL, Wolbink G, Krieckaert CL, Turk S, Navarro-Compán V, L'Ami M, Nurmohamed MT, van der Horst-Bruinsma I, Jurado T, Diego C, Bonilla G, Villalba A, Peiteado D, Nuño L, van der Kleij D, Rispens T, Martín-Mola E, Balsa A, Pascual-Salcedo D. Plasencia C, et al. J Rheumatol. 2015 Sep;42(9):1638-46. doi: 10.3899/jrheum.141128. Epub 2015 Jul 15. J Rheumatol. 2015. PMID: 26178279
Infectious complications of biologic agents.
Martin-Mola E, Balsa A. Martin-Mola E, et al. Rheum Dis Clin North Am. 2009 Feb;35(1):183-99. doi: 10.1016/j.rdc.2009.03.009. Rheum Dis Clin North Am. 2009. PMID: 19481004 Review.
The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab.
Plasencia Ch, Pascual-Salcedo D, Alcocer P, Bonilla MG, Villalba A, Peiteado D, Arribas F, Díez J, Lopez-Casla MT, Martín-Mola E, Balsa A. Plasencia Ch, et al. Ann Rheum Dis. 2013 Nov;72(11):1888-90. doi: 10.1136/annrheumdis-2013-203353. Epub 2013 Jun 5. Ann Rheum Dis. 2013. PMID: 23740237 No abstract available.
199 results